Moreover, the 36-month beta value for MGNX is 2.05. Analysts have varying opinions on the stock, with 4 analysts rating it as a “buy,” 5 as “overweight,” 2 as “hold,” and 0 as “sell.”
The public float for MGNX is 58.71M and currently, short sellers hold a 10.98% of that float. On April 18, 2024, MGNX’s average trading volume was 1.59M shares.
MGNX) stock’s latest price update
The stock price of Macrogenics Inc (NASDAQ: MGNX) has plunged by -3.48 when compared to previous closing price of 16.68, but the company has seen a -11.78% decline in its stock price over the last five trading sessions. Seeking Alpha reported 2024-04-05 that Positive safety update released from phase 2 TAMARACK study, using vobra duo for the treatment of patients with metastatic castration-resistant prostate cancer. Updates to interim data from the phase 2 TAMARACK study expected by May 31st of 2024. Radiographic progression-free survival data from the phase 2 TAMARACK study, expected by fall of 2024.
MGNX’s Market Performance
Macrogenics Inc (MGNX) has seen a -11.78% fall in stock performance for the week, with a 3.21% gain in the past month and a 52.61% surge in the past quarter. The volatility ratio for the week is 5.95%, and the volatility levels for the past 30 days are at 6.97% for MGNX. The simple moving average for the last 20 days is 0.46% for MGNX stock, with a simple moving average of 71.47% for the last 200 days.
Analysts’ Opinion of MGNX
BTIG Research, on the other hand, stated in their research note that they expect to see MGNX reach a price target of $24, previously predicting the price at $12. The rating they have provided for MGNX stocks is “Buy” according to the report published on March 04th, 2024.
H.C. Wainwright gave a rating of “Neutral” to MGNX, setting the target price at $14 in the report published on February 14th of the current year.
MGNX Trading at -5.50% from the 50-Day Moving Average
After a stumble in the market that brought MGNX to its low price for the period of the last 52 weeks, the company was unable to rebound, for now settling with -26.42% of loss for the given period.
Volatility was left at 6.97%, however, over the last 30 days, the volatility rate increased by 5.95%, as shares surge +3.34% for the moving average over the last 20 days. Over the last 50 days, in opposition, the stock is trading -3.88% lower at present.
During the last 5 trading sessions, MGNX fell by -11.78%, which changed the moving average for the period of 200-days by +200.93% in comparison to the 20-day moving average, which settled at $16.05. In addition, Macrogenics Inc saw 67.36% in overturn over a single year, with a tendency to cut further gains.
Insider Trading
Reports are indicating that there were more than several insider trading activities at MGNX starting from Peters Jeffrey Stuart, who sale 51,395 shares at the price of $15.55 back on Apr 04 ’24. After this action, Peters Jeffrey Stuart now owns 0 shares of Macrogenics Inc, valued at $799,148 using the latest closing price.
Peters Jeffrey Stuart, the Senior VP and General Counsel of Macrogenics Inc, sale 19,625 shares at $21.50 during a trade that took place back on Mar 06 ’24, which means that Peters Jeffrey Stuart is holding 8,895 shares at $421,938 based on the most recent closing price.
Stock Fundamentals for MGNX
Current profitability levels for the company are sitting at:
- -2.86 for the present operating margin
- 0.99 for the gross margin
The net margin for Macrogenics Inc stands at -0.15. The total capital return value is set at -0.69. Equity return is now at value -6.15, with -3.04 for asset returns.
Based on Macrogenics Inc (MGNX), the company’s capital structure generated 0.18 points at debt to capital in total, while cash flow to debt ratio is standing at -2.3. The debt to equity ratio resting at 0.22. The interest coverage ratio of the stock is 117.65.
Currently, EBITDA for the company is -168.24 million with net debt to EBITDA at 0.4. When we switch over and look at the enterprise to sales, we see a ratio of 15.86. The receivables turnover for the company is 5.67for trailing twelve months and the total asset turnover is 0.2. The liquidity ratio also appears to be rather interesting for investors as it stands at 4.48.
Conclusion
To wrap up, the performance of Macrogenics Inc (MGNX) has been better in recent times. The stock has received a bullish of “buy” and “hold” ratings from analysts. It’s important to note that the stock is currently trading at a significant distance from its 50-day moving average and its 52-week high.
